Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

SABCS 2025 | SABCS 2025: sentinel lymph nodes and next-generation oral SERDs

Sunil Badve • 12 Dec 2025

SABCS 2025

Breast Cancer Giredestrant

lidERA

Sunil Badve, MD, FRCPath, Emory School of Medicine, Atlanta, GA, provides his highlights from the 2025 San Antonio Breast Cancer Symposium (SABCS) meeting, including data on lymph nodes and sentinel lymph nodes, which suggest that examining the sentinel lymph node can provide a reliable indication of the status of the axilla, potentially eliminating the need for complete axillary dissection in many patients. Additional trials of interest include the lidERA trial (NCT04961996) which assessed giredestrant, a next-generation oral SERD. This interview took place at the 2025 SABCS Meeting in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.